Answers are grounded in this paper and cite their sources.
Bärthel E, Rauchfuß F, Hoyer H, Habrecht O, Jandt K, Götz M, Voigt R, Heise M, Marx G, Settmacher U. Impact of stable PGI2analog iloprost on early graft viability after liver transplantation: a pilot study. Clin Transplant 2012: 26: E38–E47. © 2011 John Wiley & Sons A/S. Abstract: Background: Ischemia/reperfusion injury after liver transplantation (LT) may be associated with primary graft dysfunction (PDF) or non‐function. Prostaglandins were demonstrated to be beneficial in reducing ischemic injury by improving microcirculation and protecting endothelial cells. The aim of this study was to analyze the effect of the continuously administered prostaglandin I2analog iloprost on allograft function after LT. Methods: Eighty patients were prospectively randomized and assigned to two groups. Patients in the treatment group received iloprost for seven d after transplantation, and those in the control group did not. The primary end point was graft dysfunction. Results: The incidence of PDF was 20% (n = 8) in the control group and 5% (n = 2) in the treatment group, respectively (p = 0.087). Four patients in the control group underwent re‐transplantation for initial non‐function (INF). There was no evidence for INF in the treatment group. Iloprost was associated with improved allograft function. Clinical course and outcome were comparable. Conclusions: We suggest iloprost to be beneficial for early post‐transplant liver function. If the rate of PDF can be significantly reduced with this treatment concept, it should be analyzed in a larger number of patients (ISRCTN95672167).
No takes yet. Share an insight, caveat, or question.
Barthel et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: